Aaron David Greenblatt, MD

BA magna cum laude with honors in History, Yale University, New Haven, CT

Postbaccalaureate Premedical Program, Goucher College, Baltimore, MD

MD, University of Pennsylvania School of Medicine, Philadelphia, PA

Residency, Family Medicine, Santa Rosa Family Medicine Residency Program (UCSF Affiliate)

Fellowship, Addiction Medicine, University of Maryland Medical Center, Baltimore, MD

I have been a faculty member at the University of Maryland School of Medicine since completing my fellowship in Addiction Medicine in 2015.  Now full-time, I divide my clinical responsibilities between the Division of Addiction Research and Treatment (DART) in the Department of Psychiatry and the Department of Family and Community Medicine. As medical director of the UMMC Addiction Treatment Programs at 1001 West Pratt Street, I treat patients, coordinate clinical care, host research projects, and participate in the clinical education of medical students, psychiatry residents, and addiction fellows. We have implemented a co-located primary care, psychiatry, and infectious disease practice (the University of Maryland Health and Recovery Clinic, or HARP) alongside our addiction treatment programs. In addition, as the director of the Addiction Medicine Fellowship, I am responsible for fellow recruiting, program accreditation, and clinical teaching.

In the Department of Family and Community Medicine, I precept medical students and residents in their training. In addition, I am undertaking writing and curriculum development, especially in domains that relate to the intersection of primary care, care of chronic illness in patients with addiction, and enhanced treatment of substance use disorders.

primary care, addiction, substance use disorders, opioid use disorders, reverse colocation, family medicine, smoking cessation

Weintraub E, Greenblatt AD, Chang J, Himelhoch S, Welsh C. Expanding access to buprenorphine treatment in rural areas with the use of telemedicine. Am J Addict. 2018 Dec;27(8):612-617. doi: 10.1111/ajad.12805

Visconti AJ, Sell J, Greenblatt AD. Primary Care for Persons Who Inject Drugs. Am Fam Physician. 2019 Jan 15;99(2):109-116

Cai NS, Quiroz C, Bonaventura J, Bonifazi A, Cole TO, Purks J, Billing AS, Massey E, Wagner M, Wish ED, Guitart X, Rea W, Lam S, Moreno E, Casadó-Anguera V, Greenblatt AD, Jacobson AE, Rice KC, Casadó V, Newman AH, Winkelman JW, Michaelides M, Weintraub E, Volkow ND, Belcher AM, Ferré S. Complexes of mu-opioid and galanin receptors determine the dopaminergic effects of opioids. J Clin Invest. 2019 Mar 26;130. pii: 126912. doi: 10.1172/JCI126912

Belcher AM, Cole TO, Greenblatt AD, Hoag SW, Epstein DH, Wagner M, Billing AS, Massey E, Hamilton KR, Kozak Z, Welsh CJ, Weintraub E, Wickwire EM, Wish ED, Kaptchuk TJ, Colloca L. Open-label dose-extending placebos for opioid use disorder: A protocol for a randomized controlled clinical trial with methadone treatment. BMJ Open. 2019 Jun 21;9(6):e026604. doi: 10.1136/bmjopen-2018-026604

Ruhela D, Bhopale V, Yang M, Yu K, Weintraub E, Greenblatt AD, Thom S. Blood-borne and brain-derived microparticles in morphine-induced anti-nociceptive tolerance. Brain Behavior and Immunity. 2020 Jan 27. DOI: 10.1016/j.bbi.2020.01.017

Weintraub E., Greenblatt A.D., Chang J., Welsh C.J., Berthiaume A.P., Goodwin S.R., Arnold R., Himelhoch S.S., Bennett M.E., and Belcher A.M. Outcomes for patients receiving telemedicine-delivered medication-based treatment for opioid use disorder: a retrospective chart review. Heroin Addiction and Related Clinical Problems, Published Ahead of Print, March 27, 2020

Greenblatt AD, Magidson JF, Belcher AM, Gandhi D, Weintraub E, Overdue for an Overhaul: How Opioid Treatment Programs Can Learn From COVID-19, Mayo Clinic Proceedings. 2020 October 25. doi: https://doi.org/10.1016/j.mayocp.2020.08.011

Cole TO, Robinson D, Kelley-Freeman A, Gandhi D, Greenblatt AD, Weintraub E and Belcher AM (2021) Patient Satisfaction With Medications for Opioid Use Disorder Treatment via Telemedicine: Brief Literature Review and Development of a New Assessment. Front. Public Health 8:557275. doi: 10.3389/fpubh.2020.557275

Deutsch-Link S, Belcher AM, Massey E, Cole TO, Wagner MA, Billing AS, Greenblatt AD, Weintraub E, Wish ED. Race-based differences in drug use prior to onset of opioid use disorder. Accepted for Publication. Journal of Ethnicity in Substance Use, 2021.